Recurrent immune thrombocytopenic purpura with excellent prognosis

Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by increase in destruction of circulatory platelets and is the most common cause of acquired thrombocytopenia in childhood. ITP can be classified based on duration of thrombocytopenia as acute and chronic form. Recurrent ITP is defined as recurrence of symptoms, after at least three months of remission sustained without any treatment. It is a rare entity and seen in just 5% of all ITP cases. Further, its treatment is often cumbersome and warrants use of non-conventional drugs and splenectomy. Reported here is a case of ITP in a 10-year-old girl, who presented with three recurrences and all episodes were successfully treated with either oral Prednisolone or resolved spontaneously.

Prognosis of chronic immune thrombocytopenia in the setting of COVID-19 infection

“…ITP relapse was defined as recurrence of bleeding symptoms or drop in platelet count to < 100 x 10 9 /L after sustaining remission for three months at least with or without treatment. 8 Partial response to treatment was defined based on platelet count of >30 x 10 9 /L and doubling of the baseline value and complete response to treatment was defined based on a platelet count of >100x 10 9 /L. 9 Development of bleeding events like gastrointestinal (GIB), skin, mucocutaneous, central nervous system (CNS), genitourinary, epistaxis, hemoptysis, and muscles hematoma were investigated in the setting of COVID-19 infection.…”